Maintenance therapies in bipolar disorders

@article{Gitlin2012MaintenanceTI,
  title={Maintenance therapies in bipolar disorders},
  author={Michael J Gitlin and Mark A. Frye},
  journal={Bipolar Disorders},
  year={2012},
  volume={14}
}
Gitlin M, Frye MA. Maintenance therapies in bipolar disorders. Bipolar Disord 2012: 14 (Suppl. 2): 51–65. © 2012 The Authors. Journal compilation © 2012 John Wiley & Sons A/S. 
Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder
TLDR
Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder are made.
Enhancing stability in bipolar disorder
TLDR
Mood stabilizers are the first-line treatment during manic, hypomanic and mixed episodes of BD and both quetiapine and lamotrogine are indicated for the prophylaxis of depressive bipolar episodes.
Pharmacogenomics of bipolar disorder.
TLDR
A selective review of pharmacogenomic findings in bipolar disorder focused particularly on the pharmacogenomics literature relevant to this trait, in light of the evidence suggesting a genetic effect of lithium reponse in BD.
Maintaining mood stability in bipolar disorder: a clinical perspective on pharmacotherapy
TLDR
This review primarily included studies that were randomised, placebo-controlled, blinded, non-enriched and of sufficient duration to be regarded as maintenance therapy and their impact in determining treatment decisions was moderated accordingly.
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: bipolar disorder summary
TLDR
This guideline summary is an abridged version that focuses on bipolar disorder intended as an aid to the management of this complex disorder for primary care physicians working in collaboration with psychiatrists to implement successful long term management.
Olanzapine is superior to lamotrigine in the prevention of bipolar depression: a naturalistic observational study
TLDR
This prospective naturalistic study suggests that olanzapine is more effective than lamotrigine in the prevention of depressive episodes in patients with bipolar disorder.
Essential Pharmacotherapies for Bipolar Disorder
TLDR
The current state of evidence for medications treating bipolar disorder is discussed, highlighting the evidence, exploring contraindications, side effects, and monitoring requirements for each of the major agents available, and a growing range of second-generation antipsychotics.
Korean Medication Algorithm for Bipolar Disorder 2014: comparisons with other treatment guidelines
TLDR
The treatment recommendations of the Korean Medication Algorithm Project for Bipolar Disorder 2014 are similar to those of other treatment guidelines and reflect current changes in prescription patterns for bipolar disorder based on accumulated research data.
Practitioner review: Long-term pharmacological treatment of pediatric bipolar disorder.
TLDR
According to the limited empirical evidence, aripiprazole can be useful for relapse prevention in children with PBD, and clinical decision making should be based on individual clinical aspects and safety concerns.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 93 REFERENCES
Clinical practice recommendations for bipolar disorder
TLDR
Clinical relevant evidence‐based recommendations for the management of bipolar disorder in adults that are informative, easy to assimilate and facilitate clinical decision‐making are provided.
Depressive relapse during lithium treatment associated with increased serum thyroid‐stimulating hormone: results from two placebo‐controlled bipolar I maintenance studies
Objective:  To assess the relationship between depressive relapse and change in thyroid function in an exploratory post hoc analysis from a controlled maintenance evaluation of bipolar I disorder.
Use of Topiramate in Treatment-Resistant Bipolar Spectrum Disorders
TLDR
Preliminary results indicate that adjunctive topiramate may be useful in the long-term treatment of bipolar spectrum disorders, even in the most difficult-to-treat patients.
Open-Label Adjunctive Topiramate in the Treatment of Unstable Bipolar Disorder
TLDR
Adjunctive topiramate treatment can reduce the severity of manic and depressive symptoms, as well as reducing tremor and weight in outpatients with BD I or II.
Lithium specificity in bipolar illness: a classic agent for the classic disorder.
TLDR
It is demonstrated that lithium possesses significant clinical and therapeutic efficacy that is very individual and thus remains the treatment of choice for bipolar disorder when used specifically in select patients and its phenotypic specificity of action.
Efficacy of aripiprazole adjunctive to lithium or valproate in the long‐term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double‐blind, randomized study
TLDR
The safety and effectiveness of aripiprazole adjunctive to lithium or valproate in the long‐term treatment of patients with bipolar I disorder with an inadequate response to Lithium or Valproate monotherapy is investigated in a multicenter, double‐blind, randomized study.
Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials.
TLDR
Mood stabilizers have differing profiles of efficacy and tolerability, suggesting complementary roles in long-term maintenance treatment, according to systematic review of randomized controlled trials.
Number needed to treat analyses of drugs used for maintenance treatment of bipolar disorder
TLDR
All of the pharmacological agents assessed were effective in the prevention of any kind of mood episode; however, different efficacy profiles were found for prevention of manic and/or depressive relapses.
Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6).
TLDR
Lamotrigine was better tolerated than lithium, but apparently this did not influence the outcome, and practically no patients were maintained successfully on monotherapy with either of the drugs.
Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD.
TLDR
A history of psychosis, age at onset, bipolar I versus II subtype, history of rapid cycling, prior hospitalizations, current illness state, and history of alcohol or substance use disorders did not significantly alter the risk profiles for receiving complex regimens.
...
1
2
3
4
5
...